September 23, 2024
BioTissue Earns Top Ranking on Great Place to Work® and 2024 Fortune Best Workplaces in BioPharma™ List
Employee Feedback Highlights Company’s Commitment to
Workplace Culture and Leadership
MIAMI, September 23, 2024–BioTissue, a leader in regenerative healing, using cryopreserved human birth tissue products for ocular surface disease, chronic wounds, and musculoskeletal conditions, has ranked #14 on Great Place To Work® and Fortune Magazine’s 2024 Fortune Best Workplaces in BioPharma™ List. This prestigious recognition, awarded based on employee feedback gathered through independent evaluations, highlights companies excelling in workplace culture. As the global benchmark for such recognition, Great Place to Work® sets the standard for identifying organizations where employees thrive.
“We are thrilled to be recognized for our commitment to creating a positive and supportive culture,” said BioTissue CEO Ted Davis. “Over the past year, BioTissue has continued to evolve, yet our dedication to providing the resources, support, and opportunities for our employees to grow has remained constant. This esteemed recognition reaffirms our ability to adapt while staying focused on the well-being and success of our team.”
BioTissue employees have the opportunity to make a meaningful impact in people’s lives while being on the cutting edge of biotechnology advancements. Their Trust Index™ Employee Survey results reflect the pride and fulfillment they experience in being part of such a dynamic and innovative workplace. An incredible 91% of BioTissue employees reported the company as a great place to work compared to 57% of employees at a typical US-based company.1 In open-ended comments, words like “people,” “culture,” and “team” were most frequently mentioned when employees were asked what makes the company special. Additionally, 94% of employees expressed pride in telling others they work at BioTissue.
Being named both a Great Place to Work Certified™ company and a Fortune Best Workplace in BioPharma™ offers BioTissue research-backed validation for cultivating an exceptional employee experience. This recognition supports the foundation for achieving our vision of unlocking the full potential of regenerative therapy.
For career opportunities, visit https://biotissue.com/about-us/careers/.
# # #
About BioTissue Holdings Inc.
BioTissue is an emerging biotechnology company and leader in harnessing the unique power of human birth tissue to support regenerative healing for ocular surface disease and in surgical, chronic wound, and musculoskeletal applications. BioTissue’s portfolio of Cryopreserved Amniotic Membrane (CAM) products use its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with multiple Investigational New Drug (IND) clinical trials as the company pursues Biologic License Applications (BLAs) for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 900,000 human implants with its products and published over 400 peer-reviewed studies supporting BioTissue’s platform technology. Learn more at biotissue.com.
Media Contact
Laura DiCaprio
McDougall Communications for BioTissue
[email protected] or (585) 434-2153
